Full-Time

Field Reimbursement Manager

Neurology

Posted on 6/11/2025

Deadline 6/18/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$122.3k - $203.8k/yr

Senior, Expert

Midland, TX, USA

Candidates must be based in the US and may need to travel within the assigned geography for meetings and training.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BA/BS Degree required, preferably in life science or business, MBA a plus
  • Minimum 7+ years' experience in the pharmaceutical/healthcare industry
  • Ability to travel to meetings/trainings/programs as necessary - additional travel will be required within the assigned geography
  • Demonstrated success of cross functional teamwork and working in a matrix environment (sales, market access, customer service, medical affairs, marketing, etc.)
  • Must be energetic and driven to succeed
  • Interpersonal skills including managing and resolving conflict and building strong working relationships
  • Obtain ability to adapt to change and react constructively in a high-energy and fast paced environment
  • Excellent strategic thinking, analytical, and communication skills required
  • Strong understanding and experience supporting products in the provider office and health care facility settings of care
  • Significant experience and understanding of the ever changing payer environment and its impact on patient access to products in provider offices and health care facility settings of care
  • Achieve and maintain compliance with all applicable Sanofi-Genzyme policies and procedures, regulatory and legal requirements, and help to monitor compliance during cross functional team interactions
  • Valid driver's license
Responsibilities
  • FRMs will be subject matter experts on product procurement as it relates to buy & bill processes, billing and coding education, claims and adjudication by site of care, financial assistance offerings from patient support program, provider contracting and issue resolution pertaining to the purchase and billing of SanofiNeuorlogy products by health care providers and/or healthcare facilities.
  • Act as the main point of contact for the Patient Support Services Hub, and communicate and collaborate cross-functionally to lead Lemtrada Pull Through efforts
  • Plan and implement geographic business plans to support appropriate access to Sanofiproducts
  • Compliantly educate office personnel on appropriate billing codes
  • Provide support in triaging contracting, billingand coding, access and procurement questions and other issues where appropriate.
  • Establish positive and productive working relationships with all key customer segments (internal and external).
  • Develop working relationships with state societies, associations, and advocacy groups, as needed, to support patient access and raise overall awareness for Sanofi.
  • As needed, conduct HCP office visits to facilitate pull through efforts and problem solve escalated issues as a HIPAA compliant contact.
  • Work compliantly to reduce cycle time and increase conversion rate for patients prescribed Sanofi products.
Desired Qualifications
  • 4-7+ years pharmaceutical/biotech business relations experience, with demonstrated exceptional results
  • MS experience
  • MS or Oncology physician reimbursement experience
  • Buy and Bill experience
  • Infusion product experience
  • Market access experience
  • Leadership (direct or indirect) experience
  • Ability to manage relationships, administrative business and projects remotely

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing advanced research and development to create effective therapies and vaccines that improve patient health. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse portfolio that includes prescription medicines and over-the-counter products. The company aims to enhance health outcomes and quality of life for people globally by ensuring that its products are safe, effective, and accessible.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, indicating strong financial performance.
  • The integration of AI in R&D accelerates drug discovery and reduces costs.
  • mRNA technology expansion offers new drug development opportunities for Sanofi.

What critics are saying

  • Increased competition in immunology may impact Sanofi's market share.
  • Potential regulatory delays could affect the launch of new drugs like tolebrutinib.
  • Acquisitions may lead to integration challenges and operational disruptions.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The on-body injector for Sarclisa offers a novel delivery method for multiple myeloma.
  • Dupixent's approval for chronic spontaneous urticaria marks a significant therapeutic advancement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.

INACTIVE